CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on July 13, 2021
Acasti Pharma Inc.
3009 boul. De la Concorde E., Suite 102
Laval, Québec, Canada H7E 2B5
July 13, 2021
VIA EDGAR
Fredrick Philantrope
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: | Acasti Pharma Inc. |
Registration Statement on Form S-4
Filed June 30, 2021 (as amended July 13, 2021)
File No. 333-257589
Dear Mr. Philantrope:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Acasti Pharma Inc., respectfully requests that the effective date of the Registration Statement on Form S-4 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on July 15, 2021, or as soon as practicable thereafter.
If you have any questions or require additional information, please contact Jason Comerford, Esq. of Osler, Hoskin & Harcourt LLP at (646) 528-8742. Thank you for your assistance and cooperation in this matter.
Very truly yours,
ACASTI PHARMA INC. |
||
By: | /s/ Jan DAlvise | |
Jan DAlvise Chief Executive Officer |
cc: | Jason Comerford, Esq., Osler, Hoskin & Harcourt LLP |
François Paradis, Esq., Osler, Hoskin & Harcourt LLP